logo

Liver Diseases Therapeutics Market Size (2024 - 2029)

The liver disease treatment market is anticipated to experience growth driven by an increase in the prevalence of liver diseases, influenced by factors such as rising alcohol consumption and poor dietary habits. The COVID-19 pandemic has further impacted this market, as it affected the treatment of other diseases and highlighted the vulnerabilities of liver disease patients. Efforts by governments and non-profit organizations to raise awareness and support research and development are also contributing to market expansion. However, stringent regulations and drug-related complications may pose challenges to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Liver Disease Drugs Research Liver Cirrhosis Treatment Industry Market Size

Market Size of Liver Diseases Therapeutics Industry

Liver Diseases Therapeutics Market Summary
Study Period 2018 - 2028
Base Year For Estimation 2022
Forecast Data Period 2024 - 2028
CAGR 8.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Liver Diseases Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Liver Diseases Therapeutics Market Analysis

During the forecast period, the market for medicines to treat liver disease is expected to register a CAGR of about 8.5%.

Since all resources were used to treat COVID-19 patients, it had a big effect on how other diseases were treated. Also, because of the lockdown and the high risk of infection, fewer people went to hospitals and clinics for problems other than COVID-19. This was expected to have a big effect on the market that was being studied. Reports said that COVID-19 may have had a big effect on people with liver diseases, which was good for the market for medicines to treat liver diseases. For example, a May 2021 study by the American Association for the Study of Liver Diseases (AASLD) found a strong link between cirrhosis and immune system problems.This was linked to a poor COVID-19 prognosis as well as alcoholic liver damage and cirrhosis. Also, according to an article in Frontiers in Medicine from September 2021, liver damage in COVID-19 patients can be caused by a number of things, such as systemic inflammation caused by the virus, hypoxia, hepatic congestion, and drug-induced liver disease. The same source also said that COVID-19 was linked to hepatic decompensation and liver-related death in people with cirrhosis.Hence, COVID-19 was predicted to have an effect on the liver disease therapeutics market.

The main things that are likely to drive growth in the liver disease therapeutics market are the high number of people with liver diseases, the rise in alcohol consumption, and bad eating habits. For example, a research study published in the Clinical Liver Disease journal in June 2021 says that chronic liver disease (CLD), which affects about 1.5 billion people around the world, is one of the leading causes of death and illness around the world.Further, as per the American Association for the Study of Liver Diseases's publication in June 2021, the most common causes of prevalent disease are non-alcoholic fatty liver disease (NAFLD) (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Additionally, according to the study published in Clinical and Molecular Hepatology in October 2022, the prevalence of nonalcoholic fatty liver disease (NAFLD) is forecasted to be 55.7% by 2040, globally. Therefore, increasing liver diseases have helped drive the overall market.

Also, people who drink more alcohol and are overweight are more likely to get liver disease, which is expected to increase the demand for medicines to treat it. A study that was published in June 2022 in the journal Hepatology found that, for example, a temporary increase in alcohol consumption can greatly increase the risk of long-term illness and death from ALD.During the COVID-19 pandemic, it was also said that up to 25% more alcohol was drunk in the United States. Also, the same source says that by 2040, this increase in drinking could lead to 8,000 more deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer, which is likely to increase the need for effective and advanced treatments.

Also, because liver diseases are becoming more common, the government and other non-profits play a very important role in raising awareness about them all over the world. For example, in January 2023, the International Liver Transplantation Society (ILTS), the International Living Donor Liver Transplantation Study Group (iLDLT), and the Liver Transplant Society of India (LTSI) held Asia's first consensus conference on how to care for patients who get small liver grafts in India. Hence, all these organizations are found promoting awareness of liver-related diseases and support for research and development for the prevention, treatment, and cure of liver diseases. So, the main things that are driving the growth of the market during the study period are the rise in liver diseases around the world, the rise in the number of people who drink too much and eat poorly, and the rise in government efforts to raise awareness about liver diseases.

However, the stringent regulations and the complications associated with the drugs are expected to hinder market growth during the study period.

Liver Diseases Therapeutics Industry Segmentation

As per the scope of the report, liver disease is either inherited or caused by factors that damage the liver, such as viruses and the use of alcohol. Liver disease, if not treated, damages the liver and further leads to liver failure. Therefore, some of the major drugs used in treating various types of liver diseases include vaccines, immunosuppressants, chemotherapy drugs, and anti-viral drugs. The liver disease therapeutics market is segmented by treatment type (anti-viral drugs, targeted therapy, immunosuppressant drugs, chemotherapy drugs, immunoglobulin, vaccines, and other treatment types), end user (hospitals, ambulatory surgery centers, and other end users), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
Anti Viral Drugs
Targeted Therapy
Immunosuppressant Drugs
Chemotherapy Drugs
Immunoglobulin
Vaccines
Other Treatment Types
By End-User
Hospitals
Ambulatory Surgery Centers
Other End-Users
Geography
North America
United States (By Treatment Type and End-User)
Canada (By Treatment Type and End-User)
Mexico (By Treatment Type and End-User)
Europe
Germany (By Treatment Type and End-User)
United Kingdom (By Treatment Type and End-User)
France (By Treatment Type and End-User)
Italy (By Treatment Type and End-User)
Spain (By Treatment Type and End-User)
Rest of Europe (By Treatment Type and End-User)
Asia-Pacific
China (By Treatment Type and End-User)
Japan (By Treatment Type and End-User)
India (By Treatment Type and End-User)
Australia (By Treatment Type and End-User)
South Korea (By Treatment Type and End-User)
Rest of Asia-Pacific (By Treatment Type and End-User)
Middle-East and Africa
GCC (By Treatment Type and End-User)
South Africa (By Treatment Type and End-User)
Rest of Middle-East and Africa (By Treatment Type and End-User)
South America
Brazil (By Treatment Type and End-User)
Argentina (By Treatment Type and End-User)
Rest of South America (By Treatment Type and End-User)
Need A Different Region Or Segment?
Customize Now

Liver Diseases Therapeutics Market Size Summary

The liver disease treatment market is poised for significant growth, driven by an increasing prevalence of liver diseases globally, influenced by factors such as rising alcohol consumption and poor dietary habits. The COVID-19 pandemic has also impacted the market, as it highlighted the vulnerabilities of individuals with liver conditions, potentially boosting the demand for liver disease therapeutics. The market is characterized by a strong focus on antiviral drugs, particularly for hepatitis B and C, which remain prevalent and pose serious health risks. These antiviral treatments are crucial in managing liver disease progression and improving patient outcomes. The market's expansion is further supported by ongoing research and development efforts aimed at addressing unmet medical needs and enhancing treatment efficacy.

North America stands as the largest regional market, attributed to its robust clinical research infrastructure and high awareness levels among patients. The region's market growth is expected to continue, driven by the increasing incidence of liver diseases and the introduction of innovative therapeutic solutions. Key players in the market, including Abbott Laboratories, Gilead Sciences, and Novartis AG, are actively engaged in developing advanced treatments to cater to the growing demand. Despite the promising growth prospects, the market faces challenges such as stringent regulatory requirements and drug-related complications. Nonetheless, the concerted efforts by governments and non-profit organizations to raise awareness and support research initiatives are anticipated to further propel the market forward during the forecast period.

Explore More

Liver Diseases Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in the Incidence of Liver Diseases

      2. 1.2.2 Increase in the Consumption of Alcohol and Improper Diet

      3. 1.2.3 Rising Government Initiatives to Provide Vaccines and Growing Awareness

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects and Risks Associated with Drugs

      2. 1.3.2 Stringent FDA Approvals and Other Government Regulations

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Treatment Type

      1. 2.1.1 Anti Viral Drugs

      2. 2.1.2 Targeted Therapy

      3. 2.1.3 Immunosuppressant Drugs

      4. 2.1.4 Chemotherapy Drugs

      5. 2.1.5 Immunoglobulin

      6. 2.1.6 Vaccines

      7. 2.1.7 Other Treatment Types

    2. 2.2 By End-User

      1. 2.2.1 Hospitals

      2. 2.2.2 Ambulatory Surgery Centers

      3. 2.2.3 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States (By Treatment Type and End-User)

        2. 2.3.1.2 Canada (By Treatment Type and End-User)

        3. 2.3.1.3 Mexico (By Treatment Type and End-User)

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany (By Treatment Type and End-User)

        2. 2.3.2.2 United Kingdom (By Treatment Type and End-User)

        3. 2.3.2.3 France (By Treatment Type and End-User)

        4. 2.3.2.4 Italy (By Treatment Type and End-User)

        5. 2.3.2.5 Spain (By Treatment Type and End-User)

        6. 2.3.2.6 Rest of Europe (By Treatment Type and End-User)

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China (By Treatment Type and End-User)

        2. 2.3.3.2 Japan (By Treatment Type and End-User)

        3. 2.3.3.3 India (By Treatment Type and End-User)

        4. 2.3.3.4 Australia (By Treatment Type and End-User)

        5. 2.3.3.5 South Korea (By Treatment Type and End-User)

        6. 2.3.3.6 Rest of Asia-Pacific (By Treatment Type and End-User)

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC (By Treatment Type and End-User)

        2. 2.3.4.2 South Africa (By Treatment Type and End-User)

        3. 2.3.4.3 Rest of Middle-East and Africa (By Treatment Type and End-User)

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil (By Treatment Type and End-User)

        2. 2.3.5.2 Argentina (By Treatment Type and End-User)

        3. 2.3.5.3 Rest of South America (By Treatment Type and End-User)

Liver Diseases Therapeutics Market Size FAQs

The Liver Diseases Therapeutics Market is projected to register a CAGR of 8.5% during the forecast period (2023-2028).

Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi and Astellas Pharma Inc. are the major companies operating in the Liver Diseases Therapeutics Market.

Liver Cirrhosis Treatment Market Report Snapshots